Interim Data Presented from Two Ongoing Ph 2 Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
“For the first time, we report the ORR of vebreltinib by GCN in NSCLC patients with MetExon14 skipping mutation. Similar efficacy analyses by GCN subgroup of other cMET inhibitors are either not readily available publicly or were reported to have lower ORR in NSCLC patients with MetExon14 skipping mutation alone without overlapping MET amplification. We are delighted these data from the two ongoing Phase 2 clinical trials showed a potential differentiation from other cMET inhibitors, and suggest vebreltinib has the potential to address patients’ unmet medical needs. The distribution of MET amplification status of patients in the NSCLC study with MetExon14 skipping mutation in the vebreltinib program is similar to those reported in U.S. public databases, thus likely close to a real-world setting,” said Guo-Liang Yu, Ph.D., co-founder, Chairman and Chief Executive Officer of Apollomics. “Particularly noteworthy is vebreltinib’s efficacy in the patient group without co-occurring MET amplification, offering hope for improved outcomes in this challenging-to-treat patient population.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the